Techniques for Evaluating Conflicting Information in Multi-Database Patents and Drug Pipeline Reports

ICIC 2010, Vienna

Diane Webb, President
27 October 2010

The Problem

- When creating pipeline and patents reports combining search results from different databases…
- *…how do you choose between conflicting information from different sources?*
- *…and present the best possible composite view of the information?*

The Problem – Patents example

	Title	Database	Patent Family			Abstract	Claims
			Patent	Kind	Date		
1	**Mouse trap used at home has enclosure which is provided with top and base having aperture and indentation that can be aligned to open enclosure for entry of mouse, such that contra-rotation of top relative to base is enabled to trap mouse.**	Derwent World Patents Index	WO 2005051079 EP 1691603	A1 A1	20050609 20060823	WO2005051079 A UPAB: 20050624 NOVELTY: The mouse trap has an enclosure having a top (1) and a base (3) respectively provided with an aperture (5) and an indentation (7). The manual rotation of the top relative to the base is enabled to open the enclosure with the alignment of the aperture and the indentation. The contra-rotation of the top relative to the base is performed upon entry of the mouse into the enclosure to trap the mouse. [..see record]	
2	**MOUSETRAP**	FAMPAT	GB 200325446 WO 200551079 AU 2004292376 EP 1691603 KR 20060110287 BR 200416076 US 20070017149 IN 2006CN01914 ZA 200603453 US 7506471 US 20090288332	D0 A1 A1 A1 A A A1 A A B2 A1	20031203 20050609 20050609 20060823 20061024 20070102 20070125 20070608 20070725 20090324 20091126	Disclosed is a mousetrap having an enclosure with a rotatable top part having a downwardly extending strike plate within the enclosure, and a bottom part having an upwardly extending catch plate within the enclosure, an aperture in each of the top part and the bottom part which are in substantial alignment when the mousetrap is set, and a trigger mechanism, wherein the mousetrap is set to incapacitate [..see record]	
3	**Mousetrap**	PatBase	GB 200325446 AU 2004292376 WO 05051079 EP 1691603 KR 2006110287 BR 200416076 US 2007017149	A0 AA A1 A1 A A A	2003-12-03 2005-06-09 2005-06-09 2006-08-23 2006-10-24 2007-01-02 2007-01-25	Source: WO05051079A1 The present invention is directed to a mousetrap comprising: an enclosure comprised of a top a base and apertures located on each of the top and the base wherein the enclosure is in an open position upon substantial alignment of the apertures; and a trigger mechanism comprising a lever arrangement and a biasing means operably connected to the top and the base wherein the lever [..see record]	
	MOUSETRAP	TotalPatent	WO 2005051079 AU 2004292376 BR PI0416076 BR PI0416076 EP 1691603	A1 A1 A1 A A1	2004-10-20	The present invention is directed to a mousetrap comprising: an enclosure comprised of a top, a base and apertures located on each of the top and the base, wherein the enclosure is in an open position upon substantial alignment of the	CLAIMS : 1. A mousetrap comprising: an enclosure comprised of a top, a base and apertures located on each of the top and the base, wherein the

BizInt Smart Charts 2010

The Problem – Drug Pipelines example

HER-2 Inhibitors (Apr 2008 updated with June 2008) - all dbs

	Product	Database	Highest Phase	Update Date	Mechanism of Action
12	**BMS-599626**	Thomson Reuters Integrity Compounds	Phase I		HER4 (erbB4) Inhibitors EGFR (HER1 erbB1) Inhibitors HER2 (erbB2) Inhibitors
13	**BMS-599626**	Citeline Pharmaprojects	No Development Reported	2007-01-22	ErbB-1 tyrosine kinase inhibitor (KI-TYE1-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN)
14	**AC-480**	Thomson Pharma	Discovery	2008-05-02	Anticancer EGFR family tyrosine kinase receptor inhibitor Erbb2 tyrosine kinase receptor inhibitor Erbb4 tyrosine kinase receptor inhibitor Epidermal growth factor antagonist
15	**BMS 599626**	Adis R&D Insight	Phase I	2008-05-08	Epidermal growth factor inhibitors HER2 inhibitors
16	**Pan-HER kinase inhibitor, Bristol-Myers Squibb**	IMS R&D Focus	Phase I	2007-01-01	EGF receptor inhibitor

BizInt Smart Charts 2010

Survey conducted in September 2010

- SurveyGizmo survey with 13 questions – 6 patents related and 7 drug pipeline related
- Sent 300+ survey invitations to BizInt Smart Charts users; posted survey invitation on PIUG wiki and SLA DPHT list
- 75 complete responses

BizInt Smart Charts 2010

What kinds of reports do you create?

Answer	Count	Percent
Pipeline	31	41%
Patents	22	29%
Both	22	29%



BizInt Smart Charts 2010

Question 1: Patent Titles & Abstracts

- Derwent World Patents Index and Chemical Abstracts both provide enhanced titles and abstracts, while other databases, such as Patbase or MicroPatent, present the original or translated titles and abstracts.

When a record with enhanced titles and abstracts is part of a group, do you?

BizInt Smart Charts 2010

Question 1: Patent Titles & Abstracts

Answer	Count	Percent
b. select the title/abstract that best fits the search	19	45%
a. always select the enhanced title/abstract	11	26%
d. decide based on cost or license terms	9	21%
d. no preference	2	5%
c. never select the enhanced title/abstract	1	2%

BizInt Smart Charts 2010

Comments: Patent Titles & Abstracts

- "It all depends on the original query and sometimes I might even show both the original title and enhanced title."
- "We have a license with Patbase so that tends to influence the decision"
- "The title that best fit the search is very often the one from Derwent because more comprehensive."
- "The choice also depends on what the client wants to see."

BizInt Smart Charts 2010

Question 3: Patent Families

- The families reported by databases are often different.

Which of these best describes how you select which publication numbers to show in your results?

BizInt Smart Charts 2010

Question 3: Patent Families

Answer	Count	Percent
b. Select the most comprehensive family	17	40%
c. Create a composite family combining all of the publications in all of the records	12	29%
a. Select the family from a particular database provider	10	24%
e. Select only publications for authorities of interest	2	5%
f. No Preference	1	2%

BizInt Smart Charts 2010

Comments: Patent Families

- "It depends on whether I am doing a state-of-the-art, patentability, FTO, or validity search."
- "I focus on US & PCT members when possible."
- "Authorities of interest are - for the time being - US, EP, WO."
- "It's important to be as comprehensive as possible for patent searches (and so in report too)."
- "It would be nice if there was an automated way to create a composite family."

BizInt Smart Charts 2010

Question 5: Claims - Language

- Assuming that you and/or your client are English-speakers -- If a patent has been granted, and the granted publication is currently only available in another language (e.g., German),

  Which claims would you present to your client?

BizInt Smart Charts 2010

Question 5: Claims - Language

Answer	Count	Percent
b. Machine translation of the granted claims	10	25%
c. Claims from any application in English	10	25%
a. The granted claims, even though they are not in English	9	22%
e. No preference	6	15%
d. English claims from an application to a specific authority	6	15%

BizInt Smart Charts 2010

Comments: Claims - Language

- "It would depend on what a particular attorney requested."
- "If the results are for a Freedom-To-Operate search, then the granted claims are most important. If the results are for a Prior Art or Landscape search, then the claims from an application in English are preferable."
- "US clients usually want to see US granted claims if available"

BizInt Smart Charts 2010

Applying the Rules

	Title	Database	Patent Family: Patent	Kind	Date	Abstract	Claims
1.	Mouse trap used at home has enclosure which is provided with top and base having aperture and indentation that can be aligned to open enclosure for entry of mouse, such that contra-rotation of top relative to base is enabled to trap mouse.	1.1 DWPI | link 1.2 TOTALPAT | link 1.3 Patbase | link 1.4 FAMPAT	GB 200325446	D0	20031203	WO2005051079 A UPAB: 20050624 NOVELTY: The mouse trap has an enclosure having a top (1) and a base (3) respectively provided with an aperture (5) and an indentation (7). The manual rotation of the top relative to the base is enabled to open the enclosure with the alignment of the aperture and the indentation. The contra-rotation of the top relative to the base is performed upon entry of the mouse into the enclosure to trap the mouse. [..see record]	CLAIMS : 1. A mousetrap comprising: an enclosure comprised of a top, a base and apertures located on each of the top and the base, wherein the enclosure is in an open position upon substantial alignment of the apertures;and a trigger mechanism comprising a lever arrangement and a biasing means operably connected to the top and the base, wherein the lever arrangement defines a gap through which a [..see record]
			WO 200551079	A1	20050609		
			AU 2004292376	A1	20050609		
			EP 1691603	A1	20060823		
			KR 20060110287	A	20061024		
			BR 200416076	A	20070102		
			US 20070017149	A1	20070125		
			IN 2006CN01914	A	20070608		
			ZA 200603453	A	20070725		
			US 7506471	B2	20090324		
			US 20090288332	A1	20091126		
	1.1 DWPI		1.4 FAMPAT			1.1 DWPI	1.2 TOTALPA
2.	Portable electrical trap for capturing and killing a mouse, has vacuum source which sucks the mouse fully into a collection chamber within which the mouse is subsequently suffocated.	2.1 DWPI | link 2.2 MPAT | link 2.3 TOTALPAT | link	US 6865843	B1	2005-03-15	US 6865843 B UPAB: 20050406 NOVELTY: Primary and secondary motion sensors (28,34) detect the presence of a mouse inside the interior cavity of the mouse trap (10). A primary gate and a secondary gate (36) in turn automatically opens upon activation of the corresponding motion sensor. A vacuum source (40) sucks the mouse fully into a collection chamber (38) within which the mouse is subsequently suffocated. [..see record]	1. A portable electrical mouse trap for capturing and killing a mouse, comprising: a housing in the shape of a cat having a head with a pair of eyes and a mouth defining an interior cavity, the mouth forming an entrance to the interior cavity; a primary motion sensor near the entrance to the interior cavity for selectively closing the mouth; a retractable primary gate in electrical

BizInt Smart Charts 2010

Question 2: Preferred Database

- Everything else being equal, in what order would you choose to take information from the pipeline databases? (1 = 1st choice, 2 = 2nd choice, etc.)
  - Thomson Pharma/IDdb3
  - Thomson Prous Integrity
  - IMS R&D Focus
  - Adis R&D Insight
  - Citeline Pipeline/Pharmaprojects
  - other

BizInt Smart Charts 2010

Question 2: Preferred Database

Database	1st	2nd	3rd	4th	5th	6th	Avg Rank
Thomson Pharma/IDdb	27	15	8	1	1		1.7
Adis R&D Insight	16	9	16	10	2		2.5
Citeline Pipeline/ Pharmaprojects	8	15	14	8	2	2	2.7
Thomson Prous Integrity	3	9	5	12	18	2	3.8
IMS R&D Focus		4	8	17	16		4.0
Other		1		1	4	21	5.6

BizInt Smart Charts 2010

Comments: Preferred Database

- "For very early stage compounds, I lean toward Integrity, whereas for compounds in clinical trials I rely on IDdb or Adis."
- "I prefer databases where I know that the end-user has a license ."
- "Adis just seems to have the most recent information and the most flushed out records."
- "I like the commercial summaries of Citeline Pipeline and IMS R&D Focus; they consistently cite their information sources."

BizInt Smart Charts 2010

Question 3: Mechanism of Action

- In this example, if your goal is to identify compounds in development for the target "HER2", how would you select the Mechanism of Action to appear in the reference row?

	Product	Common Drug Name	Database	Originator	Mechanism of Action	Last Update
383	**TAK 285**	TAK-285	IMS R&D Focus	Takeda (Japan)	protein kinase inhibitor tyrosine kinase inhibitor signal transduction inhibitor	2009-08-24
384	**TAK-285**	TAK-285	Thomson Pharma	Takeda Pharmaceutical Co Ltd	Anticancer Erbb2 tyrosine kinase receptor inhibitor Anticancer protein kinase inhibitor AMP activated protein kinase stimulator	2010-04-02
385	**TAK 285**	TAK-285	Adis R&D Insight	Takeda (Originator)	Epidermal growth factor receptor antagonists HER2 inhibitors	2010-02-16
386	**TAK-285**	TAK-285	Thomson Reuters Integrity Compounds	Millennium Pharmaceuticals Takeda	EGFR (HER1 erbB1) Inhibitors HER2 (erbB2) Inhibitors	
387	**TAK-285**	TAK-285	Citeline Pipeline	Takeda	ErbB-1 tyrosine kinase inhibitor ErbB-2 tyrosine kinase inhibitor	2010-02-05

BizInt Smart Charts 2010

Question 3: Mechanism of Action

Answer	Count	Percent
Select the cell that has HER2 listed even if it is not the only mechanism listed	27	50%
Select the cell with the largest list of Mechanisms of Action	7	13%
No preference	6	11%
Prefer a specific database regardless of what Mechanism of Actions are listed	6	11%
Select the cell that has HER2 listed as the only Mechanism of Action	4	7%
Select the Mechanism of Action cell from the most recently updated record	4	7%

BizInt Smart Charts 2010

Comments: Mechanism of Action

- "If I'm looking for a specific MOA, I want to see that spelled out."
- We create our own column for MoA, so we have a standard set that we pull from, but still include the list from the database.
- After selecting the cell with the most MOAs, I would cut and paste any I missed from the other records (if they are correct .)
- I'd select the entry with the most accurate details.

BizInt Smart Charts 2010

Question 6: Highest Phase for Indication

- Launched products frequently also have multiple indications at lower phases of development. In the example, the Highest Phase for Lapatinib (Tykerb) is “Launched”.

If you are asked to prepare a summary of drugs in development for the treatment of brain cancer what would you want in the “Highest Phase” or other sortable phase column?

BizInt Smart Charts 2010

Question 6: Highest Phase for Indication

Highest Phase	Drug Development Phase	
	Indication	Phase
Launched	Cancer, breast	Launched
	Cancer, lung, general	Phase III
	Cancer, head and neck	Phase III
	Cancer, renal	Phase III
	Cancer, bladder	Phase III
	Cancer, gastrointestinal, stomach	Phase III
	Cancer, oesophageal	Phase III
	Cancer, brain	Phase II
	Cancer, ovarian	Phase II
	Cancer, peritoneal	Phase II
Launched	Breast cancer (Combination therapy, Second-line therapy)	Launched
	Brain cancer (Metastatic disease:Brain metastases arising from breast cancer)	Phase III
	Breast cancer (Combination therapy, First-line therapy)	Phase III
	Breast cancer (Adjunctive treatment)	Phase III
	Gastric cancer (Combination therapy)	Phase III
	Head and neck cancer	Phase III
	Solid tumours	Phase II

BizInt Smart Charts 2010

Question 6: Highest Phase for Indication

Answer	Count	Percent
The phase from the most recently updated record	37	69%
The phase of the indication I am interested in	10	19%
The "highest" phase of development listed for any indication	5	9%
No preference	2	4%

BizInt Smart Charts 2010

Comments: Highest Phase for Indication

- "A separate and sortable phase column that is tied to the indication is the most useful."
- "It is important to note that the drug has been launched for another indication."
- "I like to keep track of both the highest indication and the phase the product is in for a given indication."

BizInt Smart Charts 2010

Applying the Rules

	Product	Database	Highest Phase	Update Date	Mechanism of Action
3.1	AC-480 ✔	Thomson Pharma	Discovery	2008-05-02	Anticancer ✔ EGFR family tyrosine kinase receptor inhibitor Erbb2 tyrosine kinase receptor inhibitor Erbb4 tyrosine kinase receptor inhibitor Epidermal growth factor antagonist
3.2	BMS- 6	Adis R&D Insight	Phase I ✔	2008-05-08 ✔	Epidermal gro or inhibitors HER2 inhibitors
3.3	BMS- 6	Thomson Reuters Integrity Compounds	Phase I		HER4 (erbB4) I rs EGFR (HER1 erbB1) Inhibitor HER2 (erbB2) Inhibitors
3.4	Pan-HER kinase inhibitor, Bristol-Myers Squibb	IMS R&D Focus	Phase I	200 1	EGF receptor inhibitor
3.5	BMS-599626	Citeline Pharmaprojects	No Development Reported	2007-01-22	ErbB-1 tyrosine kinase inhibitor (KI-TYE1-AN) ErbB-2 tyrosine kinase inhibitor (KI-TYE2-AN)

BizInt Smart Charts 2010

Applying the Rules

	Product	Database	Highest Phase	Update Date	Mechanism of Action
1.	ARRY-380	1.1 TPharm | link 1.2 Adis | link 1.3 Integr | link 1.4 Integr | link 1.5 PProj 1.6 PProj	Phase I Clinical Trial	2008-05-08	Anticancer Erbb2 tyrosine kinase receptor inhibitor
	1.1 TPharm		1.5 PProj	1.5 PProj	1.1 TPharm
2.	BIBW-2992	2.1 TPharm | link 2.2 Adis | link 2.3 Integr | link 2.4 IMS 2.5 PProj	Phase II/III	2008-06-10	Anticancer EGFR family tyrosine kinase receptor inhibitor Erbb2 tyrosine kinase receptor inhibitor
	2.1 TPharm		2.2 Adis	2.2 Adis	2.1 TPharm
3.	AC-480	3.1 TPharm | link 3.2 Adis | link 3.3 Integr | link 3.4 IMS 3.5 PProj 3.6 PProj	Phase I	2008-05-08	Anticancer EGFR family tyrosine kinase receptor inhibitor Erbb2 tyrosine kinase receptor inhibitor Erbb4 tyrosine kinase receptor inhibitor Epidermal growth factor antagonist
	3.1 TPharm		3.2 Adis	3.2 Adis	3.1 TPharm

Charts 2010